In today’s fast-paced, innovation-fueled biopharma landscape, the traditional model of C-suite leadership is being turned on ...

One of the goals of the current administration is to implement the use of AI in FDA’s approval process. Proponents of the ...

The Medipost CEO discusses developing treatments for knee osteoarthritis and other conditions.

The supplemental New Drug Application is supported by Phase III data, which showed Caplyta significantly prolonged time to ...

While the growing oncology pipeline offers tremendous potential, the path from clinical development through to commercial ...

Ekterly becomes the first FDA-approved oral on-demand treatment for hereditary angioedema in patients aged 12 years and older ...

Biljana Naumovic, US President, oncology, solid tumor, Johnson & Johnson Innovative Medicine, outlines how the company is ...

The National Alliance on Mental Illness (NAMI) issued a response to the bill, stating that the cuts to Medicare and Medicaid ...

Traditionally, COVID vaccines have been delivered via injections. According to the Cincinnati Children’s Hospital Medical ...

Biljana Naumovic, US President, oncology, solid tumor, Johnson & Johnson Innovative Medicine, shares how the company is ...

The Phase II THULITE trial will analyze the safety and efficacy of BI 1815368, an investigational oral therapy designed to ...

Accelerated approval was based on results from the Phase I/II LINKER-MM1 trial, which showed a 70% objective response rate in ...